Is Cara Therapeutics (Cara) stock a good buy?
According to the issued ratings of 3 analysts in the last year, the consensus rating for Cara Therapeutics stock is Buy based on the current 1 hold rating and 2 buy ratings for CARA. The average twelve-month price target for Cara Therapeutics is $25.67 with a high price target of $35.00 and a low price target of $16.00.
What is the price targets for Cara?
The high price target for CARA is $40.00 and the low price target for CARA is $30.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
What is the ticker symbol for Cara Operations?
Cara Operations trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CARA." How do I buy shares of Cara Operations? Shares of CARA and other Canadian stocks can be purchased through an online brokerage account.
How do I buy Cara shares?
Shares of CARA and other Canadian stocks can be purchased through an online brokerage account.
Is Cara stock a good buy?
Cara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Will Cara stock go back up?
Cara Therapeutics Inc (NASDAQ:CARA) The 8 analysts offering 12-month price forecasts for Cara Therapeutics Inc have a median target of 27.00, with a high estimate of 30.00 and a low estimate of 13.00. The median estimate represents a +213.95% increase from the last price of 8.60.
Why did Cara Therapeutics stock drop?
Shares of Cara Therapeutics (CARA -5.59%) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study evaluating oral Korsuva in treating moderate-to-severe pruritis in patients with atopic dermatitis.
What is Cara company?
About us. Cara Therapeutics is an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.
Where is Cara Therapeutics located?
Cara Therapeutics is located in Shelton, Connecticut, United States .
Will Korsuva be approved?
FDA approves KORSUVA™ Injection for the Treatment of Pruritus in Hemodialysis Patients. The Food and Drug Administration (FDA) recently approved a new therapeutic injection for the treatment of moderate-to-severe pruritis associated with chronic kidney disease in adults undergoing hemodialysis.
Who owns Cara group?
the Phelan familyCara was founded by the Phelan family, who teamed in 2010 with investment firm Fairfax Financial Holdings. Under the terms of the IPO, both those two groups will maintain their control over the company because the public shares being offered won't have the same voting rights.
What is Cara Foods called now?
Recipe Unlimited Corporation— Cara Operations Ltd. recently changed its name to Recipe Unlimited Corporation. The iconic Canadian company, which owns 19 brands and is Canada's largest operator of full-service restaurants, announced it would make the change during its acquisition of The Keg earlier this year.
What companies does Cara own?
Cara franchises and/or operates some of the most recognized brands in the country including Swiss Chalet, Harvey's, St‐Hubert, Milestones, Montana's, Kelsey's, East Side Mario's, New York Fries, Burger's Priest, Prime Pubs, Original Joe's, State & Main, Elephant & Castle, Bier Markt, Landing restaurants and Pickle ...
Is CARA stock a buy right now?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are c...
Will Cara Therapeutics' stock price go up in 2022?
4 analysts have issued 12-month target prices for Cara Therapeutics' shares. Their forecasts range from $20.00 to $30.00. On average, they predict...
How has Cara Therapeutics' stock performed in 2022?
Cara Therapeutics' stock was trading at $12.18 at the start of the year. Since then, CARA shares have decreased by 29.6% and is now trading at $8.5...
Are investors shorting Cara Therapeutics?
Cara Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 5,350,000 shares, an...
When is Cara Therapeutics' next earnings date?
Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Cara...
How were Cara Therapeutics' earnings last quarter?
Cara Therapeutics, Inc. (NASDAQ:CARA) issued its earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.52) earnings per...
Who are Cara Therapeutics' key executives?
Cara Therapeutics' management team includes the following people: Mr. Christopher A. Posner , Pres, CEO & Director (Age 52, Pay $431.9k) Dr. Der...
Who are some of Cara Therapeutics' key competitors?
Some companies that are related to Cara Therapeutics include ChemoCentryx (CCXI) , HUTCHMED (HCM) , Aurinia Pharmaceuticals (AUPH) , Arcus Bios...
What other stocks do shareholders of Cara Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Enterta...
Who sold Cara Therapeutics stock?
When will Cara Therapeutics release its earnings?
Company insiders that have sold Cara Therapeutics company stock in the last year include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Joana Goncalves, Martin Vogelbaum, and Scott Terrillion. View insider buying and selling activity for Cara Therapeutics or view top insider-selling stocks.
How much does Cara Therapeutics make?
Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021. View our earnings forecast for Cara Therapeutics.
What is Cara Therapeutics?
Cara Therapeutics has a market capitalization of $597.60 million and generates $135.08 million in revenue each year. The biopharmaceutical company earns $8.41 million in net income (profit) each year or $0.18 on an earnings per share basis.
Is Cara a big mover?
Cara Therapeutics Inc (NASDAQ: CARA) shares dive after as investors react to topline results from its KARE Phase 2 trial evaluating oral Korsuva (difelikefalin tablets) for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis (AD) patients. The trial's primary efficacy endpoint was the change from baseline in the weekly mean of the daily 24-hour Itch score at week 12 of the treatment period. The study failed to meet the primary endpoint in the ITT patient population. But a statistically significant improvement from baseline was evident as early as week 1 for the 1 mg dose group, which was sustained through 75% of the treatment period. In a prespecified analysis, a statistically significant change in the primary efficacy endpoint was observed in the mild-to-moderate patient population, which was evident at week 1 and sustained through the treatment period. Prespecified analysis by disease severity indicated a statistically significant improvement, with 32% of Korsuva-treated patients achieving a ≥4 point reduction in itch score at Week 12 versus 19% in the placebo group. A statistically significant improvement was also achieved for the 0.5 mg dose. Oral KORSUVA was generally well-tolerated across all doses. The company will host a conference call today at 8:00 a.m. ET Price Action: CARA shares are down 37% at $16.25 in the premarket session on the last check Thursday. See more from BenzingaClick here for options trades from BenzingaAtea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With DosingGalera Therapeutics Stock Surges After Its Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Is Cara Operations a good dividend stock?
Cara (CARA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Who are some of Cara Operations' key competitors?
Cara Operations pays an annual dividend of C$0.41 per share and currently has a dividend yield of 1.54%. View Cara Operations' dividend history.
What other stocks do shareholders of Cara Operations own?
Some companies that are related to Cara Operations include Whitbread (WTB), Greene King (GNK), SSP Group (SSPG), Domino's Pizza Group (DOM), Mitchells & Butlers (MAB), MTY Food Group (MTY), Ei Group plc (EIG.L) (EIG), J D Wetherspoon (JDW), Young & Co.'s Brewery, P.L.C.
What is Cara Operations' stock symbol?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Operations investors own include Canopy Growth (WEED), (CGC), Extendicare (EXE), Inter Pipeline (IPL), NVIDIA (NVDA), Advanced Emissions Solutions (ADES), Rentokil Initial (RTO), AbbVie (ABBV), Alliance Resource Partners (ARLP) and Curaleaf (CURLF).
How do I buy shares of Cara Operations?
Cara Operations trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CARA."
Where are Cara Operations' headquarters?
Shares of CARA and other Canadian stocks can be purchased through an online brokerage account.
How can I contact Cara Operations?
Cara Operations is headquartered at 199 Four Valley Dr, CONCORD, ON L4K 0B8, Canada.
Cara Therapeutics (NASDAQ:CARA) Price Target and Consensus Rating
Cara Operations' mailing address is 199 Four Valley Dr, CONCORD, ON L4K 0B8, Canada. The company can be reached via phone at +1-905-7602244.
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Cara Therapeutics (NASDAQ:CARA) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
